Cancers (Jun 2018)
Establishing a Dedicated Lung Cancer Biobank at the University Center Hospital of Nice (France). Why and How?
- Kevin Washetine,
- Simon Heeke,
- Christelle Bonnetaud,
- Mehdi Kara-Borni,
- Marius Ilié,
- Sandra Lassalle,
- Catherine Butori,
- Elodie Long-Mira,
- Charles Hugo Marquette,
- Charlotte Cohen,
- Jérôme Mouroux,
- Eric Selva,
- Virginie Tanga,
- Coraline Bence,
- Jean-Marc Félix,
- Loic Gazoppi,
- Taycir Skhiri,
- Emmanuelle Gormally,
- Pascal Boucher,
- Bruno Clément,
- Georges Dagher,
- Véronique Hofman,
- Paul Hofman
Affiliations
- Kevin Washetine
- Hospital-Integrated Biobank (BB-0033-00025), Université Côte d’Azur, CHU de Nice, 06001 Nice CEDEX 1, France
- Simon Heeke
- Team 4, Institute of Research on Cancer and Aging of Nice (IRCAN), Inserm U1081, CNRS UMR7284, Université Côte d’Azur, CHU de Nice, 06107 Nice CEDEX 2, France
- Christelle Bonnetaud
- Hospital-Integrated Biobank (BB-0033-00025), Université Côte d’Azur, CHU de Nice, 06001 Nice CEDEX 1, France
- Mehdi Kara-Borni
- Hospital-Integrated Biobank (BB-0033-00025), Université Côte d’Azur, CHU de Nice, 06001 Nice CEDEX 1, France
- Marius Ilié
- Hospital-Integrated Biobank (BB-0033-00025), Université Côte d’Azur, CHU de Nice, 06001 Nice CEDEX 1, France
- Sandra Lassalle
- Laboratory of Clinical and Experimental Pathology, Université Côte d’Azur, CHU de Nice, University Hospital Federation OncoAge, 06001 Nice CEDEX 1, France
- Catherine Butori
- Laboratory of Clinical and Experimental Pathology, Université Côte d’Azur, CHU de Nice, University Hospital Federation OncoAge, 06001 Nice CEDEX 1, France
- Elodie Long-Mira
- Laboratory of Clinical and Experimental Pathology, Université Côte d’Azur, CHU de Nice, University Hospital Federation OncoAge, 06001 Nice CEDEX 1, France
- Charles Hugo Marquette
- Team 4, Institute of Research on Cancer and Aging of Nice (IRCAN), Inserm U1081, CNRS UMR7284, Université Côte d’Azur, CHU de Nice, 06107 Nice CEDEX 2, France
- Charlotte Cohen
- FHU OncoAge, University of Nice Sophia Antipolis, 06001 Nice CEDEX 1, France
- Jérôme Mouroux
- Team 4, Institute of Research on Cancer and Aging of Nice (IRCAN), Inserm U1081, CNRS UMR7284, Université Côte d’Azur, CHU de Nice, 06107 Nice CEDEX 2, France
- Eric Selva
- Hospital-Integrated Biobank (BB-0033-00025), Université Côte d’Azur, CHU de Nice, 06001 Nice CEDEX 1, France
- Virginie Tanga
- Hospital-Integrated Biobank (BB-0033-00025), Université Côte d’Azur, CHU de Nice, 06001 Nice CEDEX 1, France
- Coraline Bence
- Laboratory of Clinical and Experimental Pathology, Université Côte d’Azur, CHU de Nice, University Hospital Federation OncoAge, 06001 Nice CEDEX 1, France
- Jean-Marc Félix
- Hospital-Integrated Biobank (BB-0033-00025), Université Côte d’Azur, CHU de Nice, 06001 Nice CEDEX 1, France
- Loic Gazoppi
- Hospital-Integrated Biobank (BB-0033-00025), Université Côte d’Azur, CHU de Nice, 06001 Nice CEDEX 1, France
- Taycir Skhiri
- FHU OncoAge, University of Nice Sophia Antipolis, 06001 Nice CEDEX 1, France
- Emmanuelle Gormally
- EPHE, Catholic University of Lyon, 69002 Lyon, France
- Pascal Boucher
- French National Cancer Institut, 92513 Boulogne Billancourt CEDEX, France
- Bruno Clément
- INSERM, INRA, University of Rennes, NuMeCan, CRB Santé, CHU Rennes, 35042 Rennes, France
- Georges Dagher
- INSERM, 75654 Paris, France
- Véronique Hofman
- Hospital-Integrated Biobank (BB-0033-00025), Université Côte d’Azur, CHU de Nice, 06001 Nice CEDEX 1, France
- Paul Hofman
- Hospital-Integrated Biobank (BB-0033-00025), Université Côte d’Azur, CHU de Nice, 06001 Nice CEDEX 1, France
- DOI
- https://doi.org/10.3390/cancers10070220
- Journal volume & issue
-
Vol. 10,
no. 7
p. 220
Abstract
Lung cancer is the major cause of death from cancer in the world and its incidence is increasing in women. Despite the progress made in developing immunotherapies and therapies targeting genomic alterations, improvement in the survival rate of advanced stages or metastatic patients remains low. Thus, urgent development of effective therapeutic molecules is needed. The discovery of novel therapeutic targets and their validation requires high quality biological material and associated clinical data. With this aim, we established a biobank dedicated to lung cancers. We describe here our strategy and the indicators used and, through an overall assessment, present the strengths, weaknesses, opportunities and associated risks of this biobank.
Keywords